Month: April 2020

More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patientsPhase 2 trial – As of last week, 12 patients enrolled from 2 sites; 3 more sites to initiate enrollment this week, for a total of 5 sitesPhase 2b/3 trial – First hospital cleared to enroll patients beginning todayVANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a comprehensive update and overview of the therapeutic indications from over 30 COVID-19 patients recently treated with leronlimab in over 4 hospitals and clinics throughout the country. More than 25 hospitals, to date, have requested participation in the Company’s...

Los Angeles/Desert Hot Springs, CA, April 13, 2020 (GLOBE NEWSWIRE) — Grapefruit USA, Inc., (“GPFT”, “Grapefruit” or the “Company”)) (OTCPink: GPFT) a California based cannabis company, is announcing today that in its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC last Friday, the Company reported net revenues of $451,196, an increase of 248% over revenues of $181,502 for the year ended December 31, 2018, in January of which it was first licensed by California and commenced cannabis manufacturing and distribution operations. This significant increase in revenues occurred despite the fact that the Company suspended its then current largest revenue producing operations, wholesale cannabis distribution, from April to September, in order to confirm that its cash management protocols were fully compliant...

VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) — The Board of Directors (the “Board”) of CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, appointed  Scott A. Kelly, M.D. as Chief Medical Officer and Head of Business Development for the Company.Dr. Kelly, a director since April 2017, has served as the Company’s Chairman of the Board since December 2018 and will retain his position as Chairman. Dr. Kelly has served at Atlanta-based Resurgens Orthopaedics since 2002, including as Director of the Safety Council since 2013 and as Medical Director of the Resurgens Orthopaedics’ Spine Center since 2007. Dr. Kelly received his BA in Psychology from Emory University,...

Cleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment Acceleration Program (CTAP)Pluristem’s main focus:  multinational clinical trial of PLX cells for treatment of complications associated with COVID-19                                                                               HAIFA, Israel, April 13, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has treated its first patient suffering from COVID-19 complications in the United States under the U.S. Food and Drug Administration’s (FDA) Single Patient Expanded Access Program, also called a compassionate use program, which is part of the U.S. Coronavirus Treatment Acceleration Program (CTAP),...

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitmentStudy remains on track to report interim, unblinded data from all 3 dose cohorts in MAD study in 3Q 2020SINGAPORE, April 13, 2020 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore to contain the spread of the coronavirus disease (COVID-19). ASLAN does not...

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitmentStudy remains on track to report interim, unblinded data from all 3 dose cohorts in MAD study in 3Q 2020SINGAPORE, April 13, 2020 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore to contain the spread of the coronavirus disease (COVID-19). ASLAN does not...

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitmentStudy remains on track to report interim, unblinded data from all 3 dose cohorts in MAD study in 3Q 2020SINGAPORE, April 13, 2020 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore to contain the spread of the coronavirus disease (COVID-19). ASLAN does not...

TORONTO, April 13, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex”) is pleased to announce that it has secured contracts for approximately $250,000 CAD with two existing clients. The first contract is for $130,000 CAD with one of LOTTE Group of companies, Global Logistics division. The second contract for approximately $120,000 CAD is with Hyosung Corp., and is a continuation and expansion of the original contract announced last year.“This is exciting for the team as we continue to execute on our “land and expand” strategy with global conglomerates. We look forward to continuing to build on the trust we have gained with them going forward. We are proud to be able to continue to secure new business despite the global restrictions as a result of COVID-19, our team is doing a great job working remotely...

Coronavirus (Covid19) bear market season is still mongering fear globally rummaging investors to look for safer way to save their investment. The pandemic and loss of millions of jobs worldwide pressured market to keep on dumping. The three major stocks in the U.S. market rapidly loss gains yet again on the closing of Friday’s trading day. The Dow slid 360.91 points, or 1.69%, to close at 21,052.53. The S&P 500 closed 1.51% lower at 2,488.65. The Nasdaq Composite fell 1.53% to 7,373.08. The Dow Jones Industrial just lost 2.7% this week, S&P 500 fell 2.1% while Nasdaq ended the week down 1.7%. The drop comes up after news about millions of jobs loss in U.S. jump up to nearly 10 million just this March 2020. According to analysts things will be rougher on the coming so monitoring stocks every business day is advice. As for bonds,...

We are done with the first quarter of 2020 and things are just getting harder each single day not until the Covid19 (coronavirus) in the world is contained. We are not just suffering fear because of the health issues this pandemic is creating but we are all so down with the economic bear season. It has been a hard few months for the U.S. stock market but March has been the most volatile month of the first quarter. It closes the market on Tuesday harshly. Here’s a list of the first quarter stock market drop by percentage. o The Dow closed down 13.74% in March; score its worst month since October of 2008.o The Dow closed down -23.2% for the 1st quarter, it is even worse than the fourth quarter of 1987. It was the Dow’s worst first quarter to date.o The Dow is 25.88% below its daytime all-time high of 29,568.57 from Feb 12.o The S&P...